TransMedics Group (NASDAQ:TMDX) Given “Hold” Rating at Needham & Company LLC

Needham & Company LLC restated their hold rating on shares of TransMedics Group (NASDAQ:TMDX) in a research note issued to investors on Friday, Marketbeat Ratings reports. They currently have a $109.00 price target on the stock.

Other equities analysts have also recently issued reports about the company. JPMorgan Chase & Co. reduced their target price on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 29th. Baird R W raised shares of TransMedics Group to a “strong-buy” rating in a research report on Tuesday, September 24th. Stephens raised their target price on shares of TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Piper Sandler reduced their price target on shares of TransMedics Group from $180.00 to $110.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 20th. Finally, Robert W. Baird lowered their price objective on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating for the company in a report on Tuesday, October 29th. Two analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $131.80.

TransMedics Group Price Performance

Shares of TransMedics Group stock opened at $78.58 on Friday. The company’s fifty day simple moving average is $117.72 and its two-hundred day simple moving average is $137.49. TransMedics Group has a 12-month low of $67.77 and a 12-month high of $177.37. The firm has a market cap of $2.64 billion, a PE ratio of 83.60 and a beta of 2.08. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The business had revenue of $108.76 million during the quarter, compared to the consensus estimate of $115.00 million. During the same period in the previous year, the business earned ($0.12) earnings per share. The firm’s revenue for the quarter was up 63.7% compared to the same quarter last year. As a group, equities analysts expect that TransMedics Group will post 1 EPS for the current year.

Insider Buying and Selling at TransMedics Group

In other news, Director Edward M. Basile sold 6,750 shares of the stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total value of $563,962.50. Following the sale, the director now directly owns 732 shares of the company’s stock, valued at approximately $61,158.60. This represents a 90.22 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $153.42, for a total value of $1,323,247.50. Following the transaction, the chief executive officer now owns 61,643 shares of the company’s stock, valued at $9,457,269.06. The trade was a 12.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 26,958 shares of company stock valued at $3,470,328. Corporate insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Amalgamated Bank lifted its holdings in shares of TransMedics Group by 6.7% during the second quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock valued at $168,000 after purchasing an additional 70 shares in the last quarter. Harbour Capital Advisors LLC lifted its stake in TransMedics Group by 1.7% during the 3rd quarter. Harbour Capital Advisors LLC now owns 4,841 shares of the company’s stock valued at $760,000 after acquiring an additional 81 shares during the period. Signaturefd LLC boosted its holdings in shares of TransMedics Group by 26.6% during the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after acquiring an additional 93 shares during the last quarter. Arizona State Retirement System grew its stake in shares of TransMedics Group by 2.1% in the second quarter. Arizona State Retirement System now owns 9,158 shares of the company’s stock worth $1,379,000 after acquiring an additional 186 shares during the period. Finally, Venturi Wealth Management LLC raised its holdings in shares of TransMedics Group by 33.7% during the third quarter. Venturi Wealth Management LLC now owns 869 shares of the company’s stock valued at $136,000 after purchasing an additional 219 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.